Published in Br J Haematol on March 01, 2007
Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med (2013) 0.81
Flexural cutaneous eruption due to palifermin. Br J Haematol (2007) 0.75
Palifermin-associated papular eruption. Arch Dermatol (2009) 0.75
Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol (2005) 3.15
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol (2008) 2.32
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk Res (2012) 2.18
Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol (2010) 1.66
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica (2006) 1.61
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood (2007) 1.60
Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging (2006) 1.58
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol (2005) 1.54
Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2010) 1.48
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood (2006) 1.31
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging (2012) 1.21
Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol (2002) 1.11
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood (2011) 1.01
Proteoglycans guide SDF-1-induced migration of hematopoietic progenitor cells. J Leukoc Biol (2002) 1.01
Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. Br J Clin Pharmacol (2012) 0.96
Aprotinin does not diminish blood loss in elective operations for infrarenal abdominal aneurysms: a randomized double-blind controlled trial. Ann Vasc Surg (2006) 0.89
Physical exercise interventions in haematological cancer patients, feasible to conduct but effectiveness to be established: a systematic literature review. Cancer Treat Rev (2008) 0.86
Amyloidosis of the tongue as a paraneoplastic marker of plasma cell dyscrasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2002) 0.84
Early apoptosis largely accounts for functional impairment of CD34+ cells in frozen-thawed stem cell grafts. J Hematother Stem Cell Res (2002) 0.84
Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation. Br J Haematol (2012) 0.83
Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. Eur J Haematol (2014) 0.82
Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands. Eur J Cancer (2012) 0.82
In vitro model for hematopoietic progenitor cell homing reveals endothelial heparan sulfate proteoglycans as direct adhesive ligands. J Leukoc Biol (2003) 0.81
Bone marrow stromal proteoglycans regulate megakaryocytic differentiation of human progenitor cells. Exp Cell Res (2004) 0.81
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res (2002) 0.81
Distress and quality of life after autologous stem cell transplantation: a randomized clinical trial to evaluate the outcome of a web-based stepped care intervention. BMC Cancer (2010) 0.79
Economic assessment on the management of chronic lymphocytic leukaemia. Expert Opin Pharmacother (2005) 0.79
Cognitive coping style (monitoring and blunting) and the need for information, information satisfaction and shared decision making among patients with haematological malignancies. Psychooncology (2014) 0.78
Homing and clonogenic outgrowth of CD34(+) peripheral blood stem cells: a role for L-selectin? Exp Hematol (2002) 0.77
18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol (2003) 0.77
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry. Ann Hematol (2014) 0.77
Costs of multiple myeloma and associated skeletal-related events in The Netherlands. Expert Rev Pharmacoecon Outcomes Res (2004) 0.77
Reduced supportive capacity of bone marrow stroma upon chemotherapy is mediated via changes in glycosaminoglycan profile. Matrix Biol (2007) 0.76
Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 x 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma. Br J Haematol (2002) 0.76
Monoclonal antibody therapy in haematological malignancies. Curr Clin Pharmacol (2010) 0.76
Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies. Haematologica (2005) 0.75
Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia. Mediterr J Hematol Infect Dis (2013) 0.75
[Monoclonal B-cell lymphocytosis: physiological entity or preliminary stage of chronic lymphocytic leukaemia?]. Ned Tijdschr Geneeskd (2010) 0.75
[Allogenic stem cell transplantation in the Netherlands]. Ned Tijdschr Geneeskd (2009) 0.75
Radiation therapy in early stage Hodgkin's disease: long-term results and adverse effects. Hematol J (2002) 0.75
Implantable defibrillators in cardiac amyloidosis. Int J Cardiol (2012) 0.75
Platelet activation during haemodialysis: comparison of cuprammonium rayon and polysulfone membranes. Blood Purif (2007) 0.75
Perceived need for information of patients with haematological malignancies: a literature review. J Clin Nurs (2014) 0.75
Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. Anticancer Drugs (2004) 0.75
Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. Haematologica (2005) 0.75
Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease. BioDrugs (2006) 0.75
Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma. Curr Opin Hematol (2004) 0.75
Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies. Ther Drug Monit (2008) 0.75
In vitro safety profile of G-CSF-mobilized whole blood after storage for 7 days in an infusable-grade L15 medium. Transfusion (2002) 0.75